{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:56:21Z","timestamp":1792083381699,"version":"4.4.0"},"reference-count":102,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain significant public health challenges in Asia, affecting millions and contributing to substantial morbidity and mortality. The prevalence of these infections varies across the region, with factors such as vaccination coverage, healthcare infrastructure, and sociocultural barriers influencing the epidemiology of both viruses. The persistent burden of chronic HBV, particularly in older populations, and the evolving HCV genotype landscape highlight the need for targeted, region-specific strategies. Universal screening programs have emerged as essential tools for detecting undiagnosed cases and optimizing healthcare resource allocation. Given the overlapping epidemiology of HBV and HCV, comprehensive public health interventions tailored to the unique contexts of different Asian countries are crucial for achieving global elimination goals. This review examines the epidemiological trends, challenges, and opportunities for addressing HBV and HCV in Asia, emphasizing the importance of overcoming sociocultural barriers to improve prevention, diagnosis, and treatment efforts across diverse populations.<\/jats:p>","DOI":"10.3390\/v17010034","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:37:19Z","timestamp":1735648639000},"page":"34","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Asian Perspective on Hepatitis B Virus and Hepatitis C Virus Elimination"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4058-5977","authenticated-orcid":false,"given":"Apichat","family":"Kaewdech","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-0267","authenticated-orcid":false,"given":"Phunchai","family":"Charatcharoenwitthaya","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[{"name":"NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","unstructured":"(2024, October 17). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40249-024-01225-0","article-title":"Disparities in hepatitis B virus healthcare service access among marginalised poor populations: A mixed-method systematic review","volume":"13","author":"Li","year":"2024","journal-title":"Infect. Dis. Poverty"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","article-title":"Impact of the national hepatitis B immunization program in China: A modeling study","volume":"11","author":"Liu","year":"2022","journal-title":"Infect. Dis. Poverty"},{"key":"ref_4","unstructured":"(2024, October 17). Combating Hepatitis B and C to Reach Elimination by 2030. Available online: https:\/\/www.who.int\/publications\/i\/item\/combating-hepatitis-b-and-c-to-reach-elimination-by-2030."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ijid.2023.07.028","article-title":"Halfway through HBV elimination\u2014Are we not waiting?","volume":"134","author":"Wong","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","unstructured":"Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study. Lancet Gastroenterol. Hepatol., 3, 383\u2013403."},{"key":"ref_7","first-page":"61","article-title":"A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt","volume":"31","author":"Sievert","year":"2011","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: A systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4254\/wjh.v7.i12.1708","article-title":"Hepatocellular carcinoma in Asia: Prevention strategy and planning","volume":"7","author":"Ashtari","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ayele, A., Abera, D., Hailu, M., Birhanu, M., and Desta, K. (2020). Prevalence and associated risk factors for Hepatitis B and C viruses among refugees in Gambella, Ethiopia. BMC Public Health, 20.","DOI":"10.1186\/s12889-020-08893-1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hogan, S., Page, A., Dixit, S., and McBride, K.A. (2023). HBV prevalence in Sub-continental countries: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1101\/2023.04.23.23288908"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.15585\/mmwr.mm6930a2","article-title":"Progress Toward Hepatitis B Control\u2014South-East Asia Region, 2016\u20132019","volume":"69","author":"Sandhu","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bai, S., Dang, W., Hong, W., Liao, W., and Smith, R.D. (2024). The prevalence of hepatitis B in Chinese general population from 2018 to 2022: A systematic review and meta-analysis. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09103-8"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ruan, B., Yu, Z., Yang, S., Xu, K., Ren, J., Yao, J., Wu, N., Yu, C., Deng, M., and Xie, T. (2019). Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4150-9"},{"key":"ref_15","first-page":"406","article-title":"Epidemiological survey of hepatitis B and analysis of hepatitis B vaccine coverage rate among children aged 1\u201314 years in Lhasa in 2006, 2014 and 2020","volume":"57","author":"Hu","year":"2023","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tosun, S., Ayg\u00fcn, O., \u00d6zdemir, H.\u00d6., Korkmaz, E., and \u00d6zdemir, D. (2018). The impact of economic and social factors on the prevalence of hepatitis B in Turkey. BMC Public Health, 18.","DOI":"10.1186\/s12889-018-5575-6"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/23744235.2022.2115126","article-title":"Estimates of the prevalence of occult HBV infection in Asia: A systematic review and meta-analysis","volume":"54","author":"Xie","year":"2022","journal-title":"Infect. Dis. Lond. Engl."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bello, K.E., Mat Jusoh, T.N.A., Irekeola, A.A., Abu, N., Mohd Amin, N.A.Z., Mustaffa, N., and Shueb, R.H. (2023). A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis. Healthcare, 11.","DOI":"10.3390\/healthcare11071011"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, J., Qi, J.-L., Wang, X.-X., Li, X.-H., Jin, R., Liu, B.-Y., Liu, H.-X., and Rao, H.-Y. (2023). The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1041201"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Irekeola, A.A., Malek, N.A., Wada, Y., Mustaffa, N., Muhamad, N.I., and Shueb, R.H. (2021). Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251673"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Berto, A., Day, J., Van Vinh Chau, N., Thwaites, G.E., My, N.N., Baker, S., and Darton, T.C. (2017). Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: A systematic review. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2360-6"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Saseetharran, A., Hiebert, L., Gupta, N., Nyirahabihirwe, F., Kamali, I., and Ward, J.W. (2023). Prevention, testing, and treatment interventions for hepatitis B and C in refugee populations: Results of a scoping review. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08861-1"},{"key":"ref_23","first-page":"122","article-title":"How to control highly endemic hepatitis B in Asia","volume":"38","author":"Shan","year":"2018","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.18683\/germs.2021.1277","article-title":"Surveillance for hepatitis B virus seroprevalence nearly 30 years after the implementation of a national vaccination program","volume":"11","author":"Suttichaimongkol","year":"2021","journal-title":"Germs"},{"key":"ref_25","unstructured":"GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond. Engl., 392, 1736\u20131788."},{"key":"ref_26","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond. Engl., 392, 1789\u20131858."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11901-013-0177-3","article-title":"Molecular Epidemiology of HCV in Asia","volume":"12","author":"Wei","year":"2013","journal-title":"Curr. Hepat. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12072-015-9630-4","article-title":"Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries","volume":"9","author":"Omata","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jgh.15827","article-title":"Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review","volume":"37","author":"Goel","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/14787210.2023.2225771","article-title":"Global importance of new treatment strategies to efforts to control hepatitis B virus","volume":"21","author":"Forbes","year":"2023","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_31","first-page":"E91","article-title":"Transmission of hepatitis C virus in Asia: Past and present perspectives","volume":"15","author":"Kao","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.15585\/mmwr.mm7130a2","article-title":"Progress Toward the Elimination of Mother-to-Child Transmission of Hepatitis B Virus\u2014Worldwide, 2016\u20132021","volume":"71","author":"Khetsuriani","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3748\/wjg.v11.i3.418","article-title":"Horizontal transmission of hepatitis B virus in children with chronic hepatitis B","volume":"11","author":"Doganci","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00042737-200304000-00002","article-title":"Intrafamilial transmission of hepatitis B virus in the eastern Anatolian region of Turkey","volume":"15","author":"Erol","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/infdis\/jiy620","article-title":"High Environmental Stability of Hepatitis B Virus and Inactivation Requirements for Chemical Biocides","volume":"219","author":"Than","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1743-422X-5-156","article-title":"An overview of molecular epidemiology of hepatitis B virus (HBV) in India","volume":"5","author":"Datta","year":"2008","journal-title":"Virol. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1097\/00004836-200411003-00008","article-title":"Global epidemiology of hepatitis B virus","volume":"38","author":"Custer","year":"2004","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S2468-1253(16)30031-0","article-title":"Hepatitis B and hepatitis C in southeast and southern Asia: Challenges for governments","volume":"1","author":"Wait","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"di Filippo Villa, D., and Navas, M.-C. (2023). Vertical Transmission of Hepatitis B Virus-An Update. Microorganisms, 11.","DOI":"10.3390\/microorganisms11051140"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Li, H., Huang, H., Huang, W., Du, M., Long, D., Xu, G., Mei, W., and Huang, K. (2024). Hepatitis C virus subtype diversity and transmission clusters characteristics among drug users in Zhuhai, South China. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-024-09323-y"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Jia, W., Weng, J., Fang, C., and Li, Y. (2019). A dynamic model and some strategies on how to prevent and control hepatitis c in mainland China. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4311-x"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(16)00619-X","article-title":"Public health and international drug policy","volume":"387","author":"Csete","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ishizaki, A., Bouscaillou, J., Luhmann, N., Liu, S., Chua, R., Walsh, N., Hess, S., Ivanova, E., Roberts, T., and Easterbrook, P. (2017). Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2767-0"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jceh.2014.12.004","article-title":"Tackling the Hepatitis B Disease Burden in India","volume":"4","author":"Puri","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Suthar, A.B., and Harries, A.D. (2015). A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001795"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1473-3099(15)00158-9","article-title":"Global elimination of mother-to-child transmission of hepatitis B: Revisiting the current strategy","volume":"15","author":"Thio","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jmv.24045","article-title":"Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia","volume":"87","author":"Darmawan","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_48","unstructured":"OECD, and World Health Organization (2022). Pregnancy and Birth, OECD."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/jvh.12673","article-title":"Improving access to health care for chronic hepatitis B among migrant Chinese populations: A systematic mixed methods review of barriers and enablers","volume":"24","author":"Vedio","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41124-016-0022-8","article-title":"Innovative sources for funding of viral hepatitis prevention and treatment in low- and middle-income countries: A roundtable meeting report","volume":"1","author":"FitzSimons","year":"2016","journal-title":"Hepatol. Med. Policy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet Lond. Engl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","article-title":"Recommendations for the management of hepatitis C virus infection among people who inject drugs","volume":"26","author":"Grebely","year":"2015","journal-title":"Int. J. Drug Policy"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.cld.2021.06.004","article-title":"Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa","volume":"25","author":"Charatcharoenwitthaya","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatol. Baltim. Md."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/apt.16097","article-title":"East Asia expert opinion on treatment initiation for chronic hepatitis B","volume":"52","author":"Kao","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_60","first-page":"1425","article-title":"Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_61","unstructured":"(2024, October 20). Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240090903."},{"key":"ref_62","unstructured":"(2024, October 20). THASL Guidelines\u2014Thai Association for the Study of the Liver. Available online: https:\/\/thasl.org\/thasl-guideline\/."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4254\/wjh.v13.i9.1042","article-title":"Challenges in the discontinuation of chronic hepatitis B antiviral agents","volume":"13","author":"Kaewdech","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/liv.14606","article-title":"Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation","volume":"40","author":"Kaewdech","year":"2020","journal-title":"Liver Int."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kaewdech, A., Assawasuwannakit, S., Sripongpun, P., Chamroonkul, N., Tangkijvanich, P., and Piratvisuth, T. (2022). Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front. Med., 9.","DOI":"10.3389\/fmed.2022.859430"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ye, J., and Chen, J. (2021). Interferon and Hepatitis B: Current and Future Perspectives. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.733364"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s41048-020-00112-z","article-title":"Epigenetic regulation of covalently closed circular DNA minichromosome in hepatitis B virus infection","volume":"6","author":"Wang","year":"2020","journal-title":"Biophys. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet Lond. Engl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17460441.2023.2239701","article-title":"The premise of capsid assembly modulators towards eliminating HBV persistence","volume":"18","author":"Bassit","year":"2023","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","article-title":"Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial","volume":"8","author":"Yuen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sneller, L., Lin, C., Price, A., Kottilil, S., and Chua, J.V. (2024). RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects. Microorganisms, 12.","DOI":"10.3390\/microorganisms12030599"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kayesh, M.E.H., Kohara, M., and Tsukiyama-Kohara, K. (2021). Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910462"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_85","first-page":"7","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Devan, P., Tiong, K.L.A., Neo, J.E., Mohan, B.P., Wijarnpreecha, K., Tam, Y.C.S., Coppola, N., Preda, C.M., and Wong, Y.J. (2023). Treatment Outcomes of Sofosbuvir\/Velpatasvir\/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis. Viruses, 15.","DOI":"10.3390\/v15071489"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: Two multicentre, phase 3 studies\u2014A randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_89","unstructured":"NHSO Added New Hepatitis C Medication to Scheme (2024, October 20). National Health Security Office (NHSO). Available online: http:\/\/eng.nhso.go.th\/view\/1\/DescriptionNews\/NHSO-added-new-hepatitis-C-medication-to-scheme\/279\/EN-US."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e0129522","DOI":"10.1128\/aac.01295-22","article-title":"Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects","volume":"67","author":"Cao","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4254\/wjh.v14.i7.1333","article-title":"Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings","volume":"14","author":"Said","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fvl.13.11","article-title":"Viral hepatitis in resource-limited countries and access to antiviral therapies: Current and future challenges","volume":"8","author":"Lemoine","year":"2013","journal-title":"Future Virol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Toumi, M., Wallace, J., Cohen, C., Marshall, C., Kitchen, H., Macey, J., Pegram, H., Slagle, A.F., Gish, R.G., and Ning, Q. (2024). Experience and impact of stigma in people with chronic hepatitis B: A qualitative study in Asia, Europe, and the United States. BMC Public Health, 24.","DOI":"10.1186\/s12889-023-17263-6"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"103320","DOI":"10.1016\/j.drugpo.2021.103320","article-title":"Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research","volume":"96","author":"Harris","year":"2021","journal-title":"Int. J. Drug Policy"},{"key":"ref_95","first-page":"1427","article-title":"Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China","volume":"11","author":"Song","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.35772\/ghm.2021.01078","article-title":"Messages from Japan policy for viral hepatitis","volume":"3","author":"Kanto","year":"2021","journal-title":"Glob. Health Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.4103\/jfmpc.jfmpc_1667_23","article-title":"Response-National viral hepatitis control program in India: Call for update","volume":"13","author":"Bhattacharya","year":"2024","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cld.1186","article-title":"Progressive Scale-up of HBV AND HCV Testing for Hepatitis Elimination in Vietnam","volume":"18","author":"Nguyen","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Douglass, C.H., Pedrana, A., Lazarus, J.V., \u2019t Hoen, E.F.M., Hammad, R., Leite, R.B., Hill, A., and Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med., 16.","DOI":"10.1186\/s12916-018-1162-z"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40545-021-00389-6","article-title":"Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study","volume":"14","author":"Teaima","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2055-6640(20)30281-8","article-title":"The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals","volume":"5","author":"Popping","year":"2019","journal-title":"J. Virus Erad."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s11606-022-07628-9","article-title":"Integrating Management of Hepatitis C Infection into Primary Care: The Key to Hepatitis C Elimination Efforts","volume":"37","author":"Wang","year":"2022","journal-title":"J. Gen. Intern. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:10Z","timestamp":1760115370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["v17010034"],"URL":"https:\/\/doi.org\/10.3390\/v17010034","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}